Theravance Biopharma, Inc.

Is Theravance Biopharma, Inc. technically bullish or bearish?

As of October 31, 2025, Theravance Biopharma, Inc. shows a bullish technical trend with strong MACD and Bollinger Bands indicators, despite mixed signals from RSI and KST, and has significantly outperformed the S&P 500 year-to-date and over the past year.

As of 31 October 2025, the technical trend for Theravance Biopharma, Inc. has changed from mildly bullish to bullish. The MACD is bullish on both weekly and monthly time frames, while Bollinger Bands also indicate a bullish stance on both time frames. However, the monthly RSI shows a bearish signal, and the KST is mildly bearish on the weekly but bullish monthly. Moving averages are bullish on the daily. Dow Theory reflects a mildly bullish stance on both weekly and monthly.<BR><BR>In terms of performance, Theravance Biopharma has outperformed the S&P 500 significantly year-to-date with a return of 56.75% compared to the S&P 500's 16.30%, and over the past year, it has returned 79.00% versus the S&P 500's 19.89%. Overall, the current technical stance is bullish, driven by strong MACD and Bollinger Bands indicators, despite some mixed signals from RSI and KST.

Is Theravance Biopharma, Inc. overvalued or undervalued?

As of October 17, 2025, Theravance Biopharma, Inc. is considered overvalued with a valuation grade shift from attractive to expensive, reflected in its high Price to Book Value of 3.39 and P/E ratio of 48.04, despite significant losses and negative returns on capital and equity.

As of 17 October 2025, the valuation grade for Theravance Biopharma, Inc. moved from attractive to expensive, indicating a shift towards overvaluation. The company is considered overvalued based on its current financial metrics. Key ratios include a Price to Book Value of 3.39, an EV to EBIT of -9.87, and an EV to EBITDA of -11.24, which highlight significant losses and an unfavorable valuation relative to earnings.<BR><BR>In comparison to peers, Theravance Biopharma's P/E ratio stands at 48.04, while Evolus, Inc. has a P/E of -8.24 and Aclaris Therapeutics, Inc. at -4.88, suggesting that Theravance is trading at a premium despite its losses. The industry context further emphasizes this, as the company's high valuation ratios do not align with its negative returns on capital and equity, which are -62.37% and -32.43%, respectively. Although specific return data is not available, the lack of positive returns relative to the S&P 500 reinforces the notion of overvaluation.

How big is Theravance Biopharma, Inc.?

As of Jun 18, Theravance Biopharma, Inc. has a market capitalization of 530.01 million and reported net sales of 65.27 million with a net profit of -58.34 million over the last four quarters. Shareholder's funds are 175.54 million, and total assets amount to 354.16 million.

As of Jun 18, Theravance Biopharma, Inc. has a market capitalization of 530.01 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 65.27 million, while the sum of net profit for the same period is -58.34 million.<BR><BR>As of Dec 24, the shareholder's funds are reported at 175.54 million, and total assets amount to 354.16 million.

What does Theravance Biopharma, Inc. do?

Theravance Biopharma, Inc. is a biopharmaceutical company focused on developing medicines for serious illnesses, with a market cap of $530.01 million and recent net sales of $15 million. As of March 2025, it reported a net loss of $14 million.

Overview: <BR>Theravance Biopharma, Inc. is a biopharmaceutical company engaged in creating medicines for patients suffering from serious illnesses, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 15 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -14 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 530.01 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.54 <BR>Return on Equity: -32.43% <BR>Price to Book: 3.19<BR><BR>Contact Details: <BR>Address: UGLAND HOUSE, SOUTH CHURCH STREET, GEORGE TOWN None: KY1-1104 <BR>Tel: 1 345 6508086000 <BR>Website: http://www.theravance.com

Who are in the management team of Theravance Biopharma, Inc.?

As of March 2022, the management team of Theravance Biopharma, Inc. includes Rick Winningham as Chairman and CEO, and William Young as Lead Independent Director, along with Independent Directors Robert Gunderson, Laurie Alsup, Eran Broshy, and Burton Malkiel.

As of March 2022, the management team of Theravance Biopharma, Inc. includes Mr. Rick Winningham, who serves as the Chairman of the Board and Chief Executive Officer. Additionally, Mr. William Young is the Lead Independent Director. The board also comprises Mr. Robert Gunderson, Dr. Laurie Alsup, Mr. Eran Broshy, and Dr. Burton Malkiel, all of whom hold the designation of Independent Director.

Should I buy, sell or hold Theravance Biopharma, Inc.?